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Abstract
Vemurafenib, a selective inhibitor of oncogenic BRAF kinase carrying the V600
mutation, is approved for treatment of advanced BRAF mutation–positive mel-
anoma. This study characterized mass balance, metabolism, rates/routes of elim-
ination, and disposition of 14C-labeled vemurafenib in patients with metastatic
melanoma. Seven patients with metastatic BRAF-mutated melanoma received
unlabeled vemurafenib 960 mg twice daily for 14 days. On the morning of day
15, patients received 14C-labeled vemurafenib 960 mg (maximum 2.56 MBq
[69.2 lCi]). Thereafter, patients resumed unlabeled vemurafenib (960 mg twice
daily). Blood, urine, and feces were collected for metabolism, pharmacokinetic,
and dose recovery analysis. Within 18 days after dose, ~95% of 14C-vemurafe-
nib–related material was recovered from feces (94.1%) and urine (<1%). The
parent compound was the predominant component (95%) in plasma. The
mean plasma elimination half-life of 14C-vemurafenib–related material was
71.1 h. Each metabolite accounted for <0.5% and ≤6% of the total adminis-
tered dose in urine and feces, respectively (0–96 h postdose). No new metabo-
lites were detected. Vemurafenib was well-tolerated. Excretion of vemurafenib
via bile into feces is considered the predominant elimination route from plasma
with minor renal elimination (<1%).
Abbreviations
ABA, absolute bioavailability; AUC, area under the plasma concentration–time
curve; CLcr, creatinine clearance; cuSCC, cutaneous squamous cell carcinoma; CV,
coefficient of variation; HPLC, high-performance liquid chromatography; LC-MS/
MS, liquid chromatography–tandem mass spectrometry; LSC, liquid scintillation
counting; MBP, microprecipitated bulk powder; MBq, megabecquerel; NCI CTCAE,
National Cancer Institute Common Terminology Criteria for Adverse Events; PK,
pharmacokinetic; RECIST, Response Evaluation Criteria In Solid Tumors; SPE,
solid-phase extraction; Tmax, time to the maximum plasma concentration after drug
administration; kz, apparent elimination rate; lCi, microcurie.
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Introduction
Metastatic melanoma is an aggressive disease associated
with poor prognosis, a 5-year survival rate of approxi-
mately 15%, and median overall survival of 8–10 months
(Falkson et al. 1998; Tsao et al. 2004; Atkins et al. 2008;
Patel et al. 2011). Until recently, treatment options were
limited. Response rate with dacarbazine, a chemothera-
peutic agent typically used for treatment of metastatic dis-
ease, is 7–12%, with median overall survival between 5.6
and 7.8 months (Chapman et al. 1999; Middleton et al.
2000; Avril et al. 2004; Dummer et al. 2012a).
Recent advances in the treatment of metastatic mela-
noma have seen vemurafenib (RG7204; PLX4032;
RO5185426)—a selective inhibitor of oncogenic BRAF
kinase carrying a V600 mutation (BRAFV600 kinase) (Tsai
et al. 2008; Bollag et al. 2010; Søndergaard et al. 2010)—
introduced as a treatment option. Approximately 50% of
all melanomas have an oncogenic BRAF mutation
(Thomas et al. 2007), which results in constitutive activa-
tion of the BRAF kinase and downstream signaling.
Results of phase 2 and phase 3 studies of vemurafenib
and other BRAF inhibitors have shown improved
response rates, progression-free survival, and overall sur-
vival in patients with BRAFV600–mutated metastatic mela-
noma (Chapman et al. 2011, 2012; Dummer and Flaherty
2012; Hauschild et al. 2012; Sosman et al. 2012;
McArthur et al. 2014). Progression-free and overall sur-
vival data formed the basis for approval of vemurafenib
as monotherapy for adult patients with unresectable or
metastatic BRAFV600–mutation positive melanoma in the
United States in August 2011 (Genentech, Inc. 2014).
Vemurafenib was also approved in Europe in February
2012, and has been approved or submitted for approval
in several other countries.
The successful introduction of vemurafenib as a treat-
ment option for metastatic melanoma warranted a better
understanding of the disposition of orally administered
vemurafenib. Preclinical studies characterized routes of
elimination in rats and indicated several metabolites pre-
dominantly eliminated with excretion via bile into feces
(F. Hoffmann-La Roche, data on file). In addition, pre-
clinical studies identified a number of potential minor
metabolites of vemurafenib in human liver microsomes
and hepatocytes (Fig. 1) (F. Hoffmann-La Roche, data on
file). The current study aimed to characterize the mass
balance, metabolism, rates and routes of elimination, and
disposition of 14C-labeled vemurafenib in patients with
metastatic melanoma. Population pharmacokinetic (PK)
modeling suggests that the median elimination half-life
for vemurafenib was 57 h with continual multiple-dose
vemurafenib (Genentech, Inc. 2014) and considerably
shorter after a single dose (~25 h; Ribas et al, 2014 refer-
ence). Vemurafenib exhibits extensive accumulation at
steady state, and characterization of single and multiple-
dose PK suggests that drug disposition is different at
steady state than after a single dose (Grippo et al. 2014).
This study was conducted accordingly at steady state by
administering multiple doses of unlabeled vemurafenib
to patients for 14 days followed by a single dose of
14C-vemurafenib. Patients received the potential benefit of
a therapeutic dose, and the drug disposition properties
were characterized at a time more relevant to a long-term
treatment regimen.
Figure 1. Potential vemurafenib metabolites identified from in vitro studies in human liver microsomes and hepatocytes (F. Hoffmann-La Roche,
data on file).
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Material and Methods
Study design
This was an open-label, nonrandomized, single-center,
phase 1 study in patients with metastatic melanoma.
Owing to occurrence of cutaneous squamous cell carci-
noma (cuSCC) and secondary primary melanomas in
other vemurafenib clinical studies (Flaherty et al. 2010;
Lacouture et al. 2010; Robert et al. 2011; Oberholzer et al.
2011; Zimmer et al. 2012), this study was conducted
in metastatic melanoma patients rather than healthy
volunteers.
After screening and enrollment, patients were dosed at
home with unlabeled vemurafenib 960 mg twice daily
(microprecipitated bulk powder [MBP] formulation con-
sisting of four 240-mg tablets) (Hoffmann-La Roche,
Nutley, NJ) from day 1 to day 14. Patients returned to
the clinic on the evening of day 14. On the morning of
day 15, patients received a single oral 960-mg dose of
14C-vemurafenib after ≥8 h of fasting. Patients fasted for
an additional 4 h after dosing (light snacks were allowed)
to allow full characterization of the fasted state and were
then given a meal. The radiolabeled test compound was
delivered in capsule formulation and consisted of six
120-mg capsules of unlabeled and four 60-mg capsules of
radiolabeled vemurafenib. Each 60-mg capsule contained
a maximum of 17.3 lCi of radiolabeled material to yield
a maximum dose of radioactivity of 69.2 lCi
(2.56 MBq).
14C-vemurafenib was prepared by the isotope labeling
group at Hoffmann-La Roche, with specific activity of
111.4 lCi/mg and radiochemical purity of 99.2%, as
determined by radio–high-performance liquid chromatog-
raphy (HPLC). 14C isotope labeling was incorporated on
the carbonyl carbon of vemurafenib (Fig. 1).
Collection of blood, urine, and feces samples for radio-
activity counting began on the evening of day 14 before
administration of the radioactive dose and continued
until the level of radioactivity recovered from excreta was
≤1% of radioactivity in the administered dose between
any two successive 48-h interval assessments (recovery
criterion).
On the evening of day 15, patients resumed their regu-
lar dose of unlabeled vemurafenib indefinitely until dis-
ease progression, unacceptable toxicity, or other criteria
for withdrawal from the study. Beginning on day 16 and
throughout the PK collection period up to day 36,
patients fasted overnight for ≥8 h preceding the morning
PK sample collection and for 4 h after dosing and then
were given a meal. Patients were also required to drink
≥1.5 L of fluid daily to ensure proposed urine sample
amounts were collected.
The study was conducted in accordance with accepted
standards of Good Clinical Practice and conformed to the
principles of the Declaration of Helsinki. An independent
ethics committee for the Department of Dermatology of
the University Hospital Zurich approved the study, and
all patients provided written informed consent
before study enrollment. This study is registered with
ClinicalTrials.gov, number NCT01164891.
Patients
Patients aged ≥18 years with untreated or previously trea-
ted metastatic melanoma (surgically unresectable stage
IIIc or stage IV) that was BRAFV600-mutation positive
(cobas 4800 BRAF V600 Mutation Test; Roche Molecu-
lar Diagnostics, Pleasanton, CA) were eligible for enroll-
ment. Eligible patients had an Eastern Cooperative
Oncology Group performance status of 0 or 1; evaluable
disease (measurable by Response Evaluation Criteria In
Solid Tumors [RECIST] criteria, version 1.1); and ade-
quate hematologic, renal, and liver function. A negative
pregnancy test result in premenopausal women and use
of adequate contraception was necessary before the first
dose. All patients underwent a baseline skin examination,
and preexisting cuSCC lesions were to have been excised
with adequate wound healing before dosing.
Patients were not eligible if they had active central ner-
vous system lesions; had a history of known spinal cord
compression or carcinomatous meningitis; were expected
to need additional anticancer therapy; were breast-feed-
ing; or had any medical condition capable of altering
absorption, metabolism, or elimination of the study drug.
Sample preparation for pharmacokinetic
assessments and metabolic profiling
Plasma and blood samples were collected to analyze total
radioactivity and to identify unchanged 14C-vemurafenib
and the presence of metabolites. Urinary and fecal sam-
ples were collected to analyze total radioactivity at partic-
ular time points, to analyze percentage and fraction of
dose recovered as total radioactivity, and for metabolite
profiling. Plasma pools were prepared by taking equal
aliquots (by weight) of each individual sample. Urine and
feces were pooled by taking a fixed proportion (%) of
each sample or homogenate weight.
Sample pretreatment
Plasma
A suitably sized aliquot (approximately 2 g) of each
pooled plasma sample was vortex-mixed with ~3 vol
ª 2015 Roche Innovation Center. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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acetonitrile (6 mL), then centrifuged (3000 rpm for
10 min at 4°C). The resulting supernatant (extract 1) was
transferred to a vial. The pellet was then reextracted with
an additional ~3 vol acetonitrile, and the supernatant
(extract 2) was combined with extract 1. The combined
supernatant was concentrated under a stream of nitrogen
gas (35°C), and the residue was reconstituted in 200 lL
of HPLC mobile phase. Recovery of radioactivity in
plasma was determined in the final extract by liquid scin-
tillation counting (LSC) and ranged from 83% to 128%
across each pool for individual patients. Chromatograms
presented here from HPLC analysis of metabolite profiles
represent the majority of radioactivity in the collected
plasma sample.
Feces
A suitably sized aliquot (approximately 2.5 g) of each
pooled feces sample was vortex-mixed with ~3 vol acetoni-
trile (approximately 7.5 mL), then centrifuged (3000 rpm
for 10 min at 4°C). The resulting supernatant (extract 1)
was transferred to a vial. The pellet was then reextracted
with an additional ~3 vol acetonitrile, and the supernatant
(extract 2) was combined with extract 1. The combined
supernatant was concentrated under a stream of nitrogen
gas (35°C) to approximately 4 mL. Recovery of radioactiv-
ity in feces was determined in the final extract by LSC and
ranged from 87% to 111% across each pool for individual
patients. Chromatograms presented here from HPLC ana-
lysis of metabolite profiles represent the majority of radio-
activity in the collected feces sample.
Urine
Pooled urine samples were concentrated by solid-phase
extraction (SPE). Oasis HLB 3-mL cartridges (60 mg;
Waters Corporation, Milford, MA) were preconditioned
with methanol (2 mL), then water (2 mL). Urine samples
(approximately 100 mL) were applied to the cartridges
and washed with 20 mL water. Samples were then eluted
using acetonitrile (4 9 1 mL). Eluates were reapplied to
preconditioned cartridges, washed with 10 mL water, and
eluted with acetonitrile (4 9 1 mL). Combined eluates
were concentrated under a stream of nitrogen gas (30°C).
Residues were reconstituted in 500 lL acetonitrile/water
1:1 vol/vol. Because of the low level of radioactivity in
urine samples, it was not possible to accurately determine
recovery of radioactivity after sample preparation proce-
dures in each sample. Therefore, to demonstrate no sig-
nificant loss of radioactivity during SPE, a single sample
of urine (pool 6007, patient 1001) was spiked with radio-
labeled RO5185426 reference standard. The spiked sample
was subjected to the same SPE method as study samples.
Recovery of radioactivity from the spiked sample was
determined in the final extract by LSC.
Plasma and blood samples for PK profiling were col-
lected before dosing (days 14 and 15) and at 1, 2, 4, 6,
12, 24, 36, 48, 72, 96, 168, 216, 312, and up to 504 h after
the 14C-vemurafenib dose. Plasma samples for metabolic
profiling were collected at 1, 2, 4, 6, 12, 24, 36, 48, and
72 h after the 14C-vemurafenib dose. Three pooled sam-
ples were used in profiling: 4 plus 6 h, 12 plus 24 h, and
36 plus 48 h. Urine samples were collected before the
dose and in quantitative fractions on day 15 (0–6, 6–12,
and 12–24 h) and during 24-h intervals thereafter (24–48,
48–72, and 96–120 h after dosing) until the recovery cri-
terion was met (defined previously herein). Because total
radioactivity in urine was low, a single pool from 0–6 to
72–96 h was prepared for metabolic profiling. Fecal sam-
ples were collected before dosing and during 24-h inter-
vals after dosing until the recovery criterion was met.
Two sample pools were prepared for metabolic profiling:
0–24 plus 24–48 h and 48–72 plus 72–96 h.
Concentrations of vemurafenib in human plasma from
the study were measured using a validated liquid chromato-
graphic-tandem mass spectrometry (LC-MS/MS) method.
The linear quantitation range of the assay was from 25 to
50,000 ng/mL, using plasma volumes of 0.050 mL.
Pharmacokinetic analysis
PK analysis was conducted using data from only those
patients who met the recovery criterion. All PK data were
summarized using descriptive statistics. No formal statisti-
cal analyses were applied. Standard noncompartmental
methods (WinNonlin version 5.2.1, Pharsight Corp.,
Mountain View, CA) were used to determine PK parame-
ters in blood and plasma, including time to maximum
observed plasma concentration; maximum observed
plasma concentration; apparent elimination rate (kz),
computed as the magnitude of the slope from log-linear
regression of the apparent terminal elimination phase of
the plasma concentration–time curve; elimination half-life,
computed as (ln 2)/kz; and area under the plasma concen-
tration–time curve extrapolated to infinity (AUC0–∞), or
AUC0–s, if appropriate.
Metabolite identification
Relative proportions of RO5185426 and its 14C-labeled
metabolites were characterized in human plasma, feces,
and urine samples obtained from seven patients after a
single oral dose of 14C-RO5185426 followed by 960 mg
twice daily for 15 days. Although samples were concen-
trated before radio-HPLC profiling analysis, levels of
radioactivity in the samples were low, and detected
2015 | Vol. 3 | Iss. 2 | e00113
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metabolite peaks were generally close to the limit of
detection. Analytic conditions used for LC-MS/MS are
summarized in Table 1. Tentative structures of radiola-
beled metabolites were assigned based on mass spectral
analysis (Fig. 1), and chemical structures were not con-
firmed because no metabolite standards were available.
Data were summarized using descriptive statistics where
appropriate.
Sample analysis
Radioactivity was measured for 5 min using Packard Tri-
Carb liquid scintillation counters with facilities for com-
puting quench-corrected disintegrations per minute. Effi-
ciency correlation curves were prepared and routinely
checked using [14C]–toluene and Ultima GoldTM quenched
standards (PerkinElmer LAS U Ltd., Beaconsfield, UK).
The limit of quantification was taken as twice the mean
background disintegration rate obtained from vials con-
taining liquid scintillant. Liquid scintillation counts and
weighing data were entered manually.
All data from HPLC radio detectors were captured
using Laura software (version 3.4.7.52; LabLogic Systems,
Sheffield, UK). Radiolabeled components in each chro-
matogram were evaluated to determine retention times
and peak area values (% regions of interest). The limit of
quantification for analysis of each sample type was taken
as three times the background (peak height).
LC-MS/MS data were analyzed for presence of metabo-
lites based on accurate masses of potential metabolites
using Xcalibur 2.0. software (Thermo Scientific, Waltham,
MA). Data from urine and fecal samples were summa-
rized as proportions (%) and fraction of dose recovered
as total radioactivity. Data for 14C-vemurafenib and its
metabolites were summarized over time intervals using
descriptive statistics where appropriate.
Safety assessments
Safety was determined by the reporting of adverse events;
assessment of routine laboratory values; physical examina-
tion; assessment of vital signs; electrocardiography assess-
ments; and evaluation of dermatology, head/neck, and
chest computed tomography during the study and a 28-
day follow-up period. Patients who had SCC during treat-
ment were assessed for safety until death, withdrawal of
consent, or loss to follow-up. Severity of adverse events
and changes in laboratory data were reported and sum-
marized using National Cancer Institute Common Termi-
nology Criteria for Adverse Events (NCI CTCAE, version
4.0). Safety was evaluated in all patients who received at
least one dose of study drug; descriptive statistics are pre-
sented for safety data.
Results
At the clinical cutoff date (November 2010), seven
patients with metastatic melanoma were enrolled at the
dermato-oncology unit of the Department of Dermatol-
ogy, University Hospital Zurich, Switzerland. All seven
patients were included in the safety population. Data for
two patients were excluded from the analysis of 14C-
vemurafenib PK because predose radioactive counts were
detected in the plasma samples—sample contamination is
a likely explanation for these data. Data from one patient
were excluded from urinary metabolite profiling because
of sample contamination.
All patients (three men; four women) were white; med-
ian age was 55 years (range, 39–75 years); and mean
weight (SD) was 75.5  20.1 kg. Identified target
lesions were lymph nodes (six patients), liver (two
patients), soft tissue (two patients), and pleura (one
patient).
All patients had received systemic treatment for mela-
noma (one to six prior systemic treatments) and had a met-
astatic diagnosis for >1 year (range, 38.2–133.8 months).
Table 1. Summary of the analytical conditions used for LC-MS/MS
analysis.
Instrumentation ThermoFisher LTQ Orbitrap hybrid
mass spectrometer connected to a
ThermoFisher Accela HPLC system
via an API interface
Ionization mode Positive ion electrospray
Column Waters, YMC ODS-AQ, 120A, 5-lm
packing, 4 9 150 mm
Column temperature 30°C
Solvent system
Solvent A Water + 0.1% acetic acid
Solvent B Acetonitrile + 0.1% acetic acid
Gradient elution system Time (min) % A % B
0 95 5
8 95 5
13 75 25
26 5 95
28 5 95
28.1 95 5
33 95 5
Flow rate 1.0 mL/min (split approximately 10:1
radiodetector:ms)
Scan range Full scan m/z pos 100–900, MS/MS
scan ranges were data dependent
Resolution Full scan 30,000, MSn 7500
Source voltage 4.0 kV
Capillary temperature 310C
API, application programming interface; HPLC, high-performance
liquid chromatography; LC-MS/MS, liquid chromatography–tandem
mass spectrometry; MSn, multistage MS.
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Four patients had elevated lactate dehydrogenase levels; four
patients had two metastatic sites, including liver metastasis;
and three patients had one metastatic site (pleura and
lymph).
Urinary and fecal elimination
All seven patients met the recovery criterion after 14C-
vemurafenib dosing. Good recovery of ingested radioac-
tivity was found in these patients, with a mean  SD of
95.0  2.4% (range, 91.0–98.3%; coefficient of variation
[CV]%, 2.5) of the 14C-vemurafenib–related material
recovered from urine and feces within 18 days after dos-
ing. Most of this radioactive material was found in feces
(Fig. 2). A mean of 94.1  2.7% (range, 89.4–97.6%; CV
%, 2.8) of radioactivity was recovered in feces and <1.0%
(range, 0.56–1.63%; CV%, 43.7) was recovered in urine.
The time course of cumulative 14C-vemurafenib excretion
in urine and feces showed that the majority of urinary
and fecal radioactivity was eliminated within 192 and
264 h, respectively.
Pharmacokinetics in blood and plasma
After administration of a single oral dose of 14C-vemu-
rafenib, absorption occurred with Tmax (time to maxi-
mum plasma concentration after drug administration)
between 5 and 8 h, followed by a biphasic mode of elimi-
nation with an inflection at 72 h (Fig. 3). PK parameters
for 14C-vemurafenib are detailed in Table 2. The mean
Cmax for
14C-vemurafenib–related material was
~7.8 lg eq/mL. The mean plasma elimination half-life of
14C-vemurafenib–related material was 71.1 h (range, 51–
86 h) (Table 2).
Mean  SD unlabeled plasma vemurafenib trough con-
centrations ranged from 58.2  27.1 to 67.4  22.2 lg/
mL from days 15 through 17, representing steady-state
vemurafenib plasma trough concentrations.
The mean  SD AUC ratio of blood/plasma was
0.72  0.05 (range, 0.69–0.81; Table 2). Because hemato-
crit values ranged from 0.40% to 0.51% for men and
from 0.36% to 0.47% for women, blood/plasma ratios
would be ~0.45–0.50 if plasma accounted for all 14C-
vemurafenib–related material. In this case (assuming 40–
50% of whole blood is cells and 50–60% is plasma),
approximately 10–20% of 14C-vemurafenib–related mate-
rial might be bound to the cellular compartment in whole
blood.
Metabolite characterization
Limited metabolites of 14C-vemurafenib were identified in
human plasma, and the parent compound was the pre-
dominant component in pooled plasma samples at 4–6
(mean  SD, 99.5  1.4%), 12–24 (95.9  5.5%), and
36–48 h (96.0  3.8%; Fig. 4A). Overall, potential metab-
olites in human plasma represented <5% of total chro-
matographic radioactivity and <5% of radioactivity
Figure 2. Cumulative excretion of 14C-vemurafenib via feces and
urine.
(A) (B)
Figure 3. Mean 14C-vemurafenib concentration–time profiles in plasma (closed circles) and blood (open circles) (n = 5). (A) linear scale, (B)
logarithmic scale.
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associated with the parent compound. The monohydroxy-
lated species M3 (Fig. 1) was the only metabolite detected
in plasma (Fig. 4A). The mean percentage of M3
increased with time from 0.5% to ~4% between 12 and
24 h and remained constant in the 48-h pool.
Limited metabolites of 14C-vemurafenib were identified
in human fecal samples. In the first 48 h, ≥94% of all
recovered radioactivity in feces was associated with the
parent compound (mean  SD, 94.2  5.8%), with total
metabolites accounting for ≤6% of the total administered
dose (2.6, 0.2, and 3.1% for the M6, M3, and M8 metab-
olites, respectively; Fig. 4B). Between 48 and 96 h, total
metabolites accounted for a considerably higher propor-
tion of radioactivity, with mean values of 55.5  20.1%
for the parent compound and 18.8%, 13.7%, and 11.9%
for M6, M3, and M8, respectively (Fig. 4B).
When calculated as mean  SD of the total radioactive
dose in pooled fecal samples, ~55% of the total radioac-
tive dose was found as a parent molecule, and 6.0%,
3.4%, and 4.1% as M6, M3, and M8, respectively, within
the first 96 h. In the first 48 h, the parent molecule was
38% of the total input dose and M6, M3, and M8 were
1.0%, 0.1%, and 1.2%, respectively. From 48 to 96 h, the
parent molecule was 17% of the total input radioactive
dose and M6, M3, and M8 were 5.0%, 3.3%, and 2.9%,
respectively. Due to limitations in the amount of radioac-
tive material, metabolic profiling was not conducted at
subsequent times.
Despite extensive sample collection, low levels of radio-
activity were present in pooled urine sample extracts.
Therefore, a single concentrated pool of urine was ana-
lyzed covering the whole observation period (0–96 h).
Potential metabolites each accounted for <0.5% of total
administered dose in urine, and the parent compound
accounted for ~1% of total input radioactive dose. M3
and a parent glycosylated metabolite M6 were detected
(Fig. 4C). Two additional regions of radioactivity were
observed in chromatograms of some urine samples
(<0.2% of input radioactive dose on average, with
approximate retention times of 15 and 20 min). However,
levels of radioactivity in these regions were close to the
limit of detection of the radio-HPLC system. Overall, no
new metabolites were detected in plasma or feces. Repre-
sentative full-scan data and MSn (multistage MS) data for
metabolites M3 (from feces and plasma), M6 and M8
(both from feces) are presented in Figures 5A–C.
Safety
The seven patients had a mean duration of exposure to
vemurafenib of 74.1 days (range, 28–112 days) and
received a mean cumulative dose of 138.6 g (range, 53.8–
215.0 g) (this includes the initial 14 days of unlabeled
vemurafenib). All patients experienced at least one
adverse event related to vemurafenib; most adverse events
were mild or moderate (NCI CTCAE grade 1 or 2).
The most common adverse events (occurring in ≥ two
patients) were fatigue (five patients), arthralgia (four
patients), hyperkeratosis (five patients), maculopapular
rash (four patients), and papilloma (three patients). Alope-
cia, erythema, photosensitivity reaction (Dummer et al.
2012a), pruritus, peripheral edema, abdominal distension,
(Zimmer et al. 2012) diarrhea, and cuSCC were reported
for two patients each. These adverse events are not uncom-
mon and have been universally reported across vemurafe-
nib studies (Flaherty et al. 2010; Chapman et al. 2011;
Ribas et al. 2011; Sosman et al. 2012; McArthur et al.
2014). Adverse events of grade 3 severity were reported for
five patients: cuSCC was reported for two patients; gener-
alized rash, fatigue (resulting in dose interruption), and
keratoacanthoma (see below) were reported for one patient
each. No grade 4 adverse events were reported.
Three serious adverse events (all grade 3) were
recorded for two patients. One patient had cuSCC and
one had cuSCC and keratoacanthoma. Lesions were
excised and resolved with no sequelae. All three events
were considered related to vemurafenib; however, none
resulted in dose modification/interruption or discontinua-
tion of vemurafenib.
At data cutoff, two patients were alive (>2 years after
study start). Five patients died of progressive disease. No
patient discontinued treatment because of an adverse event.
In terms of laboratory evaluations, grade 3 lymphope-
nia was recorded for four patients, low white blood cell
count was recorded for three patients, elevated low-den-
sity lipoprotein cholesterol level was noted for three
patients, and elevated c-glutamyl transferase levels were
seen in one patient. No clinically significant changes in
electrocardiography or vital signs were reported.
Table 2. 14C-vemurafenib pharmacokinetics after a single oral dose.
Parameter,
mean  SD [CV%] Blood Plasma
N 5 5
Cmax
(lg eq/mL)
5.25  1.71 [32.5] 7.83  2.28 [29.1]
Tmax (h) 4.1 (4–12)
1 4.1 (4–12)1
AUClast
(lg eq/mLh)
456  85.4 [18.7] 633  123 [19.4]
t½ (h) 84.4  24.6 [29.1] 71.1  15.4 [21.6]
Blood/plasma
AUC ratio
0.72  0.050 [6.83] N/A
AUC, area under the plasma concentration–time curve; Cmax, maxi-
mum observed plasma concentration; Tmax, time to maximum
observed plasma concentration; t½, elimination half-life.
1Median (minimum–maximum).
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Discussion
The human mass balance of vemurafenib in this study in
adults with metastatic melanoma was adequately repre-
sented because mean recovery of total radioactivity admin-
istered as 14C-vemurafenib across the seven patients was
~95.0% (range, 91.0–98.3%). Results from this study show
that vemurafenib was primarily excreted unchanged in
feces, with minimal renal excretion. Approximately 94% of
input radioactivity was recovered in feces, with ≤1% in col-
lected urine. Limited metabolism of vemurafenib was evi-
dent in plasma, feces, and urine. Approximately 55% of the
(A)
(B)
(c)
Figure 4. Metabolic profiling after a single dose of 14C-vemurafenib in (A) plasma (36–48 h), (B) feces (0–48 h; 48–96 h), and (C) urine (0–96 h).
*Electrical spike caused by static (excluded from profile as not a metabolite).
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total radioactive dose was found in feces as a parent mole-
cule, with the three main metabolites showing ≤6% each of
the input dose within the first 96 hours post-dose. During
this time, metabolites accounted for ≤0.5% of the total
administered dose in urine. Limited metabolism of vemu-
rafenib was also evident in plasma, in which >95% of the
recovered radioactivity was associated with the parent mole-
cule over a 48-h interval. Metabolic profiling could not be
conducted in pooled samples beyond 48 to 96 h because of
a limited amount of radioactive material available.
The low level of metabolite formation in the general
systemic circulation is consistent with previous studies in
animal models (F. Hoffmann-La Roche, data on file), in
which unchanged parent drug was the major component
in rat and dog plasma after oral administration. In
agreement with the present findings, studies in rats
showed that vemurafenib-derived radioactivity (parent
plus metabolites) was primarily recovered in feces
(F. Hoffmann-La Roche, data on file), with most of
the radioactivity related to unchanged parent drug
(A)
Figure 5A. Metabolite M3 (m/z 506.0738). Monohydroxylation. Representative full-scan data and MSn data were obtained from feces and
plasma samples. The observed m/z values and proposed elemental compositions are summarized. A fragmentation scheme is also shown.
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(F. Hoffmann-La Roche, data on file). Furthermore,
metabolites detected in the current study are the same as
those previously identified in vitro (hepatocytes and
microsomes) and in vivo (rats and dogs) (F. Hoffmann-
La Roche, data on file). After in vitro incubation of
vemurafenib with mouse, rat, dog, monkey, and human
liver microsomes and hepatocytes, unchanged parent
compound RO5185426 was the major component
(>91.5%), with formation of minor metabolites. No
major metabolite was detected. Monohydroxylation
metabolites (M1–M4) were the minor metabolites
detected in microsomes and hepatocytes; additionally,
minor glucuronide metabolites (M5, M7, and M8) were
also formed in hepatocytes. Metabolite M6, with addition
of 162 mass units to RO5185426, formed with only
human hepatocytes in small amounts (2.3%) and was
characterized as a glycosylation metabolite of vemurafenib
(Fig. 5B).
Metabolite identification was not the primary objective
of this study. Previous investigations in human micro-
(B)
Figure 5B. Metabolite M6 (m/z 652.1325). Glucosylation. Representative full-scan data and MSn data were obtained from feces samples. The
observed m/z values and proposed elemental compositions are summarized. A fragmentation scheme is also shown.
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somes and in rats did not yield precise chemical struc-
tures of vemurafenib metabolites. Mass spectral analysis
has been used to determine only the elemental composi-
tion of potential metabolites, providing clues to potential
metabolite identification (Fig. 1). In the current study,
low levels of metabolites were identified by LC-MS/MS:
M3 representing <5% of radioactivity in each plasma
sample, and M3 and M6 in urine and M3, M6, and M8
in feces, representing <0.5% and ≤6% of the input radio-
active dose, respectively. Urine also contained very low
levels of two unidentified metabolites. Further character-
ization of potential metabolites was not possible because
of difficulty separating peaks from background noise.
In vitro incubation studies of vemurafenib with human
complementary cDNA-expressed enzymes and P450 iso-
form-specific chemical inhibitors showed that CYP3A4
was the primary enzyme responsible for metabolism of
vemurafenib and formation of hydroxylated metabolites
M1 to M4 in human liver microsomes. No further work
has been done to characterize specific enzymes involved
(C)
Figure 5C. Metabolite M8 (m/z 666.1115). Glucuronide. Representative full-scan data and MSn data were obtained from feces samples. The
observed m/z values and proposed elemental compositions are summarized. A fragmentation scheme is also shown.
ª 2015 Roche Innovation Center. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2015 | Vol. 3 | Iss. 2 | e00113
Page 11
S. M. Goldinger et al. Vemurafenib Mass Balance in Metastatic Melanoma Patients
in formation of glucuronidated (M5, M7, M8) or glu-
cosylated (M6) metabolite species (F. Hoffmann-
La Roche, data on file).
Overall, these observations support the view that the
minor vemurafenib metabolism that occurs overall is
hepatic, with excretion via bile into feces the predominant
elimination route from plasma. The data show that the
parent drug predominates in feces even in the 48- to 96-h
pool post radioactive dose. It is interesting to speculate
that predominance of the parent molecule found in the
48-h pooled sample partially represents unabsorbed drug,
whereas the parent molecule found in the second pooled
fraction from 48 to 96 h represents parent drug generated
through hepatobiliary recirculation. This interpretation is
consistent with data from bile-cannulated rat studies
(F. Hoffmann-La Roche, data on file) and from recent
data in which metabolites M6 and M8 predominated over
the parent molecule in a bile sample from one patient
receiving vemurafenib (manuscript in preparation). The
predominant metabolites in feces seem to be glucuroni-
dated (M8) and glycosylated (M6) species that might be
substrates for gut flora, allowing for reconversion to the
parent molecule in the intestine for subsequent reabsorp-
tion into the systemic circulation. Additional studies are
planned to confirm the role of enterohepatic circulation.
Apparent clearance of vemurafenib in patients with
preexisting mild and moderate renal impairment (mild:
n = 94, creatinine clearance [CLcr] >60–89 mL/min,
moderate: n = 11, CLcr 30–59 mL/min) was similar to
that in patients with normal renal function (CLcr
≥90 mL/min), (Genentech, Inc. 2014) supporting the
finding that a dose adjustment is not necessary for
patients with mild or moderate renal impairment. Fur-
thermore, in the population PK analysis using data from
clinical trials in patients with metastatic melanoma, pre-
existing mild and moderate renal impairment did not
influence apparent clearance of vemurafenib (Genentech,
Inc. 2014). Therefore, the finding that <1% of input
radioactivity was recovered in urine suggests a minimal
role for renal excretion in vemurafenib disposition.
It was not possible to accurately determine the elimina-
tion half-life of unchanged vemurafenib from plasma
radioactivity because metabolite profiling was only con-
ducted for the first 48 h and the amount of radiolabeled
material was too low to characterize afterward. However,
during the first 48 h, >95% of plasma radioactivity was
accounted for by the parent compound. Elimination half-
life of the radioactivity was 71 h (range, 51–86 h). This
value lies within the range estimated from a population
PK model (manuscript in preparation), in which the
median of the individual elimination half-life estimate for
vemurafenib was 57 h (the 5th and 95th percentile range
was 30–120 h based on data predominantly taken from
multiple-dose kinetics of unlabeled material (Genentech,
Inc. 2014). The elimination half-life after a single dose
was considerably lower at ~25 h (Ribas et al. 2014).
Vemurafenib reabsorption during multiple dosing
through enterohepatic recirculation might account for
increased apparent elimination half-life (Roberts et al.
2002; Shou et al. 2005).
Vemurafenib was well tolerated by the seven patients in
the study. Reported adverse events are consistent with
those observed in larger clinical studies of vemurafenib
(Sosman et al. 2012; Chapman et al. 2011; McArthur
et al. 2014; Oberholzer et al. 2011; Zimmer et al. 2012;
Dummer et al. 2012b). Overall, no new safety signals were
observed.
The vemurafenib dose selected for this study (960 mg
twice daily) was based on phase 1 data, which identified
this dosing regimen as the maximum tolerated dose and
recommended dose for further clinical evaluation (Flaherty
et al. 2010). Furthermore, 960 mg twice daily is the
approved dose for treatment of advanced BRAF mutation-
positive melanoma (Genentech, Inc. 2014). Manufacturing
restrictions meant that the radioactive formulation of MBP
could not be processed to the tablet formulation. Therefore,
14C-vemurafenib was supplied as hand-filled capsules. No
differences in vemurafenib pharmacokinetics were found in
patients treated with hand-filled capsules or tablets in the
phase 1 trial PLX06-02, and use of capsules containing
radioactive vemurafenib in this study was not expected to
materially alter the metabolic profile of the investigational
drug. This theory is supported by an elimination half-life of
14C-vemurafenib within the range of PK data for unlabeled
compound (Genentech, Inc. 2014) and by a metabolite pro-
file consistent with those reported in preclinical and in vitro
studies (F. Hoffmann-La Roche, data on file).
In conclusion, this study determined the mass balance,
metabolism, and rates and routes of elimination of vemu-
rafenib in patients with metastatic melanoma. Vemurafe-
nib was primarily excreted unchanged in feces. Renal
excretion was minor, and limited metabolism of vemu-
rafenib was evident in plasma. The limited metabolism
that occurred was predominantly hepatic; therefore,
excretion via bile into the feces is the predominant elimi-
nation route from plasma for parent vemurafenib. Fur-
thermore, vemurafenib was well tolerated and no new
safety signals were observed.
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